Assertio Holdings Assertio Holdings, Inc to Report First Quarter 2025 Financial Results on May 12, 2025 Read More
Assertio Holdings, Inc. - Investor Relations Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients and has a robust portfolio of branded prescription products in neurology, oncology, hospital and pain and inflammation
Assertio Holdings » Overview Welcome to Assertio We are a leading commercial pharmaceutical company bringing differentiated products to patients We have a robust portfolio of branded prescription neurology, inflammation, pain and oncology medications
Assertio Holdings » Products To answer patient or healthcare provider questions regarding Assertio products including Customer Service, Product Information or Adverse Event Reporting, contact us at 800-518-1084 or medinfo@assertiotx com
Assertio Holdings, Inc. - News At Assertio Holdings, Inc we promise to treat your data with respect and will not share your information with any third party You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below If you experience any issues with this process, please contact us for further assistance
Assertio Holdings » Management Dr Franklin has served as Senior Vice President, Medical, of Assertio since March 2023 He oversees Assertio’s medical and clinical scientific leadership for development programs, product assessments and life cycle management
Assertio Holdings » Overview Embrace a New Career at Assertio Holdings Welcome to Assertio, where our goal as an employer is simple: To make working with us the best career experience of your life How?
Assertio Holdings » Board of Directors Mr Kirk has served as a director of Assertio since April 2024 Mr Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products
Assertio Holdings, Inc. - Events Presentations At Assertio Holdings, Inc we promise to treat your data with respect and will not share your information with any third party You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below If you experience any issues with this process, please contact us for further assistance
Assertio Holdings » Business Development Assertio is primarily interested in late-stage and approved medications across all therapeutic areas Our goal is to identify the deal structure that optimizes return and allows both parties to meet their respective needs Opportunities include: Targeted acquisitions; In-licensing partnerships; Commercialization partnerships